RARA and rhabdomyosarcoma: We demonstrated that miR-27a is implicated in cell cycle control by targeting the retinoic acid alpha receptor (RARA) and retinoid X receptor alpha (RXRA), suggesting a potential role of miR-27a in drug therapy of rhabdomyosarcoma.